Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2395MR)

This product GTTS-WQ2395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2849MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ12636MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ15203MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ8196MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ425MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ11955MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ239MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ10870MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MAb-14.18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW